Health Trials

Diffuse Intrinsic Pontine Gliomas (DIPG)

2

Review clinical trials related to Diffuse Intrinsic Pontine Gliomas (DIPG). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.

Participants needed: 60
Trial details
Phase: Phase 2Age: 12-39Biological sex: AllType: InterventionalSponsor: Nationwide Children's HospitalUpdated: May 15, 2026Locations: 20
Eligibility criteria

Patients must be ≥ 12 months and ≤ 39 years of age at the time of study enrollme... [+19]

Myelosuppressive chemotherapy: At least 21 days after the last dose of myelosupp... [+40]

Read more
Status: Not yet recruiting

Gallium Maltolate for the Treatment of Pediatric Patients With Relapsed or Refractory Pediatric High-Grade Glioma and Atypical Teratoid Rhabdoid Tumor

In this study, we want to find out more about the side effects of an investigational drug for relapsed or refractory atypical teratoid rhabdoid tumor and high-grade glioma, Gallium Maltolate (GaM) and what doses of GaM are safe for people to take. Everyone in this study will receive GaM which is still experimental and is not approved by the U.S. Food and Drug Administration. We do not know all the ways that this drug may affect people. We hope the information from this study will help us develop a better treatment for relapsed or refractory atypical teratoid rhabdoid tumor and high-grade glioma in the future.

Participants needed: 15
Trial details
Phase: Phase 1Age: 0-17Biological sex: AllType: InterventionalSponsor: Sarah RumlerUpdated: Jan 9, 2026
Eligibility criteria

Voluntary written consent must be obtained before performance of any study-relat... [+23]

Presence of other active malignant disease diagnosed within 12 months. [+9]

Read more